Quick Answer
Breast cancer treatment may combine surgery and radiation for local control with systemic treatments such as chemotherapy, endocrine therapy, targeted therapy, or immunotherapy. The appropriate plan depends on stage, tumor subtype, biomarkers, prior treatment, and the patient’s overall clinical situation.
Breast cancer treatment is not built around a single “best” therapy. Instead, clinicians combine information about where the cancer is, how far it has spread, and what biological features it carries to decide which approaches may be appropriate.
That is why two people with breast cancer may receive very different treatment plans—even when both diseases began in the breast.
The National Cancer Institute groups breast cancer care across local treatments, such as surgery and radiation, and systemic treatments, including chemotherapy, endocrine therapy, targeted therapy, and immunotherapy. Many patients receive more than one approach. NCI: Treatment for Breast Cancer
Local Treatment: Controlling Disease Where It Started
Surgery
Surgery is a central treatment for many localized breast cancers. Depending on the disease and the individual situation, this may involve breast-conserving surgery, in which the tumor and surrounding tissue are removed, or mastectomy, in which substantially more breast tissue is removed.
Surgery may also include evaluation of nearby lymph nodes to determine whether cancer has spread beyond the breast. Its role is primarily local control: removing identifiable disease from a defined anatomical area. It does not, by itself, address microscopic cancer cells that may already exist elsewhere in the body.
Radiation Therapy
Radiation therapy uses high-energy radiation to damage cancer cells in a targeted region. It is frequently used after breast-conserving surgery and may also be recommended after mastectomy in selected situations.
This illustrates an important principle of breast cancer treatment: therapies often work together rather than replacing one another. Surgery removes visible disease; radiation may reduce the likelihood that remaining local cancer cells continue to grow.
Systemic Treatment: Addressing Cancer Biology Throughout the Body
Chemotherapy
Chemotherapy interferes with rapidly dividing cells and remains important in many breast cancer settings. However, not every patient with breast cancer receives chemotherapy. Whether it is useful depends on factors including cancer subtype, stage, recurrence risk, previous treatment, and treatment goals.
Endocrine Therapy
For hormone receptor–positive breast cancer, estrogen-related signaling can help drive tumor growth. Endocrine therapies interfere with that biology in different ways—for example by reducing estrogen production, blocking the estrogen receptor, or degrading the receptor itself.
This is an early example of what is now called precision treatment: a biological feature of the tumor helps determine whether a particular type of treatment is likely to be useful. NCI: Hormone Therapy for Breast Cancer
Targeted Therapy
Targeted therapies act on specific proteins or biological pathways involved in cancer growth and survival. HER2-targeted therapy is one of the best-known examples in breast cancer. Other targeted approaches are used in selected hormone receptor–positive cancers, cancers with BRCA-related vulnerabilities, and other biomarker-defined groups.
The key principle is that the presence of a biological target can create a treatment opportunity—but it does not guarantee that every tumor carrying that target will respond in the same way.
Immunotherapy
Immunotherapy takes a different approach: rather than directly targeting a growth pathway in the cancer cell, it helps the immune system recognize or attack cancer more effectively.
In breast cancer, immune checkpoint therapy has established roles in defined triple-negative breast cancer settings rather than across all breast cancers. NCI: Immunotherapy for Breast Cancer
Why Timing Matters: Neoadjuvant and Adjuvant Treatment
Neoadjuvant therapy is administered before the main local treatment, usually surgery. One goal can be to shrink the tumor before it is removed. It can also provide information about how the cancer responds to treatment.
Adjuvant therapy is given after the main treatment to reduce the risk that remaining microscopic cancer cells lead to recurrence. These terms describe treatment strategy and timing—not entirely separate classes of drugs.
Stage and Biology Work Together
Stage remains one of the major factors guiding treatment because it describes the extent of disease. But stage alone is not enough.
- hormone receptor status
- HER2 status
- inherited or acquired genetic alterations
- menopausal status
- treatments already received
- the patient’s overall clinical situation
NCI notes that treatment planning considers both how advanced the cancer is and other factors, including breast cancer type and general health. NCI: Breast Cancer Treatment by Stage
Professional references such as the MSD Manual similarly organize breast cancer treatment across surgery, radiation, endocrine therapy, chemotherapy, HER2-directed therapy, and metastatic disease rather than presenting one universal pathway. MSD Manual Professional: Breast Cancer
Guidelines Are Decision Frameworks, Not Simple Recipes
A clinical guideline is best understood as a structured interpretation of available evidence. It may describe which treatments are supported for particular groups of patients, but recommendations depend on how that group is defined.
A statement such as “this therapy is recommended for breast cancer” is therefore usually incomplete. The important questions are: Which subtype? At what stage? Before or after which previous treatments? With which biomarker result?
This is increasingly important as breast cancer treatment becomes more biologically specific.
The Bigger Picture
Breast cancer treatment has moved from being defined mainly by where the tumor is located toward a model that combines anatomy and biology.
Surgery and radiation remain essential tools for local disease control. Chemotherapy remains important. But biomarker-guided endocrine therapy, HER2-directed therapies, immunotherapy, and other targeted approaches increasingly allow treatment to reflect what is happening inside the tumor itself.
That does not make treatment simple. It makes the central question more precise: What is driving this cancer—and which available intervention has evidence of benefit in this particular setting?
That same question is also what connects clinical treatment back to laboratory research.
This article is intended for scientific education and does not provide individualized treatment recommendations.
